

Metabolic Endocrine Education Foundation (MEEF)
638 Lindero Canyon Dr Suite # 380
Oak Park, CA 91377

NONPROFIT
ORG
US POSTAGE PAID
VAN NUYS, CA
PERMIT # 659


Register Online: www.heartindabetes.com/registration

CME Symposium

IN ASSOCIATION WITH THE

23rd
WCIRDC

EARN
CME
ABIM-MOC
CREDITS
1.75



The Complex Patient with Obesity, Cardiorenal, and Metabolic Diseases

Thursday, December 4, 2025
7:30 pm – 9:15 pm PST
Hilton Universal City Hotel
Los Angeles, California
DINNER WILL BE SERVED

All content available ON-DEMAND for ONE YEAR following the meeting.

This is a CME Symposium Supported by an Educational Grant from **AstraZeneca**
Free for all 23rd WCIRDC attendees. Register online: www.wcir.org/registration
This CME Symposium will be available and FREE for ONE year following the meeting.

JOINTLY PROVIDED



Creighton
UNIVERSITY

ADMINISTERED BY:





THE COMPLEX PATIENT WITH OBESITY, CARDIORENAL, AND METABOLIC DISEASES

CHAIRS: **Matthew R. Weir, MD • Yehuda Handelsman, MD**

7:30 pm - 9:15 pm Dinner CME Symposium - Sierra Ballroom B

Supported by **AstraZeneca**

7:30 pm Introduction & Pre-CME Questions

Matthew R. Weir, MD

7:50 pm Obesity the Root Cause of Cardiometabolic Complications Assessment and Management

Ania M. Jastreboff, MD, PhD

8:10 pm CKD and Resistant Hypertension - Intertwined Pathophysiology Key to Emerging Management

Elaine Ku, MD, MAS

8:30 pm Cardiomyopathy from rEF to pEF Understanding the Road to Management

Ahmad Masri, MD, MS

8:50 pm Panel Discussion and Q&A: Can We Protect Patients from the Ravages of Obesity and its Comorbidities

Panel: Ania M. Jastreboff, MD, PhD, Elaine Ku, MD, MAS, Ahmad Masri, MD, MS, Matthew R. Weir, MD

Moderator: Yehuda Handelsman, MD

Post-CME Questions

9:15 pm Adjourn

Program Description

The diagnosis and treatment of obesity as a chronic disease are complicated by Clinical, social and cultural Challenges. Incretin-based therapies for obesity, just like surgical approaches, have shown benefits in ASCVD, HFpEF, CKD, T2D, and fatty liver disease. Hypertension remains a major risk factor for ASCVD, CKD, and HF and worsens outcomes across DCRM conditions. The prevalence of heart failure continues to rise due to increasing rates of obesity, DM, HTN and the aging population. Emerging effective therapies are becoming available to Cardiomyopathy, Resistant HTN, HF and CKD. This satellite symposium will address the current gaps in knowledge and challenges in the management of obesity, resistant hypertension, CKD, and heart failure, with a focus on emerging tools and strategies to optimize CardioRenalMetabolic care.

Learning Objectives

Upon completion of this CME symposium, participants should be able to:

- Discuss the benefits of reducing body weight in people with obesity, including prevention or amelioration of CVMR Comorbidities
- Describe the pathophysiology of resistant hypertension, its relation to CKD addressing available and emerging treatment options
- Understand the different Etiologies of Cardiomyopathy, its impact on HF from rEF to pEF and the Road to Management

Target Audience

This educational initiative is designed for cardiologists, nephrologists, endocrinologists, internists, family physicians, and other healthcare professionals interested in epidemiology, pathophysiology, prevention, and treatment of CKD and HF and prevention of morbidity and mortality.

FACULTY



Matthew R. Weir, MD, Chair
Professor and Chief, Division of Nephrology,
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland



Yehuda Handelsman, MD, Chair
FACP, FNLA, FASPC, FAHA, MACE
Medical Director & Principal Investigator
The Metabolic Institute of America
Chair Scientific Advisory Board
DCMi- Diabetes CardioRenal & Metabolism Institute
Chair & Program Director 23rd WCIRDC
Tarzana, California



Ania M. Jastreboff, MD, PhD
Associate Professor of Medicine & Pediatrics
Endocrinology & Pediatric Endocrinology Director
Yale Obesity Research Center (Y-Weight)
Co-Director, Yale Center for Weight Management
Yale University School of Medicine
New Haven, Connecticut



Elaine Ku, MD, MAS
Professor of Medicine, Pediatrics, and Epidemiology
and Biostatistics
University of California San Francisco
San Francisco, California



Ahmad Masri, MD MS
Cardiomyopathy Section Head
Director, Hypertrophic Cardiomyopathy Center and
Cardiac Amyloidosis Program
Associate Professor of Medicine
Oregon Health & Science University
Portland, Oregon

CME DINNER SYMPOSIUM

This CME symposium is **FREE** for 23rd WCIRDC attendees and will stay on-demand for **ONE** year following the meeting.

Learn more: **WCIR.ORG/CMEsymposium**

To register for the entire 23rd WCIRDC meeting please visit: **wcir.org/registration**

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Creighton Health Sciences Continuing Education (HSCE) and Metabolic Endocrine Education Foundation (MEEF). Creighton Health Sciences Continuing Education (HSCE) is accredited by the ACCME to provide continuing medical education for physicians.

Creighton Health Sciences Continuing Education (HSCE), designated this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s).

Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information please contact:

info@tmioa.com or 818 342 1889

This is a CME Program Supported by an Educational Grant from **AstraZeneca**